NEWS

Securing a funding round is a major step for any emerging pharmaceutical or biotech company. It validates the science, builds momentum, and gives the team the resources to move the program forward. But funding also brings pressure. Investors want to see progress. Timelines become more visible. Key development decisions need to happen quickly. For many companies, this is the point where the work becomes less about the promise of the program and more about execution. Start With

Early development is centered on the science: proving the concept, advancing preclinical work, preparing for funding milestones, and moving toward clinical development. While these priorities are critical, Chemistry, Manufacturing, and Controls can quickly become one of the most important factors influencing whether a program advances smoothly or encounters costly delays. At Drug Discovery Alliances, we see that CMC decisions made early in development can have long-term impli

Innovation in pharmaceutical development rarely happens in isolation. As scientific complexity increases and development timelines become more demanding, collaboration across biotech companies, academic institutions, and large pharmaceutical organizations has become one of the most effective ways to advance programs from discovery to commercialization. Strategic alliances are helping companies move faster, reduce risk, and access specialized expertise that may not exist inter

In drug development, the difference between a program that advances on schedule and one that stalls rarely comes down to the science. More often, it comes down to whether the right expertise was available at the right moment. For emerging biotech and biopharma companies, that expertise is frequently absent precisely when it is needed most: at the inflection points where CMC strategy, regulatory documentation, and manufacturing execution demand senior-level leadership. Drug Di

As drug development programs advance, the challenges they face evolve, but the cost of misalignment remains constant. Gaps in CMC can quietly derail timelines, strain resources, and introduce unnecessary risk at critical inflection points. Recognizing this reality, Drug Discovery Alliances (DDA) is expanding its CMC consulting network to provide deeper, more flexible support across every phase of R&D, from discovery through commercial launch. CMC Expertise When and Where It’s